Table 4.

Demographic characteristics of patients undergoing chemotherapy with ovarian cancer

Characteristics	Chemotherapy resistance		No. of patients (N = 118)	P value
	Absent	Present
Age (years)				0.24
<50	34	8	42
≥50	54	22	76
Serum CA-125 level				0.20
<35	8	1	9
≥35	80	29	109
Ascites				0.9
<100	13	5	18
≥100	75	25	100
JARID1B expression				<0.001
Low	34	1	35
High	54	29	83
Lymph node metastasis				0.85
Absent	60	19	79
Present	28	11	39
Histopathological differentiationa				0.06
G1	19	4	23
G2	33	6	39
G3	36	20	56
Histology type				0.77
Serous adenocarcinoma	64	21	85
Mucoid adenocarcinoma	11	3	14
Endometrioid adenocarcinoma	12	6	18
Clear cell carcinoma	1	0	1
Residual tumor size				0.004
<1 cm	70	16	86
1–2 cm	15	8	22
≥2 cm	3	7	10
Chemotherapy regimen				<0.001
TP	50	5	55
PAC	38	27	63
FIGO stage				0.91
II	2	3	5
III	83	26	109
IV	3	1	4

TP cisplatin and paclitaxel, PAC cisplatin, epirubicin, and cyclophosphamide

^aG1 is well differentiated, G2 moderately differentiated, and G3 poorly differentiated